PHASE 3 STUDY ASSESSING THE EFFICACY OF ADDING AL3818 (CATEQUENTINIB DIHYDROCHLORIDE, ANLOTINIB HYDROCHLORIDE) TO CHEMOTHERAPIES IN SUBJECTS WITH PLATIMUM RESISTANT AND REFRACTORY OVARIAN CARCINOMA

Category Primary study
JournalInternational Journal of Gynecological Cancer
Year 2022
This article has no abstract
Epistemonikos ID: 968b3ccc012d9b5e00a3a9020e6add74a97903b2
First added on: Feb 15, 2025